Audit: QRS - Inulin-Type Fructans for Health & Longevity
Audit conducted on 15/08/2026 21:42 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 81 |
| Failed | 0 |
| N/A | 12 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER lines 348/358/362; time-to-effect to ER 405/381/350; benefits and risks to the ER tier headings; monitoring rows and cadence to ER 433–447; qualitative items verbatim from ER 451–455. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No mapped ER section carries empty-state or hedged placeholder phrasing; cautious ER scoping (“in prediabetes and type 2 diabetes”, “normal or sluggish bowels”) is carried through. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication and interaction severities (“Caution”, “Monitor”) match the ER verbatim; benefit and risk scope qualifiers that remain are the ER’s own. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, expert names, NCT identifiers, or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register matching the ER; British spellings (“favourably”, “Tumour”, “hydrolysed”) carried through from the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified doses, windows, and biomarker targets sit alongside plain-language framing in At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated descriptively (“Protocols place the dose with the largest meal” rendered as “With the largest meal”), never as an instruction to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions; the only clinician reference is the fixed template disclaimer in the footer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, or “should” anywhere in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns (“you”, “your”) occur anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are load-bearing decision qualifiers or ER biomarker names (Rome IV, Child-Pugh, HbA1c); “low-density lipoprotein cholesterol” and “C-reactive protein” are spelled out in the Benefits card. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier lines are semicolon-separated fragments; gate items are stripped to the key fact plus qualifier. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address anywhere in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional biomarker targets, titration-relevant dosing detail, and explicit decision gates address an optimizing reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing above 5 g, daily stool-form self-recording, and a nine-marker panel all assume effort tolerance. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified consumer framing; functional ranges rather than conventional reference ranges are used throughout. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance states the effect is confined to those already impaired (“hardly at all in others”), and the Benefits tiering preserves the ER’s small-effect weighting. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “for Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terms used throughout (“flatulence”, “osmotic diarrhea”, “distension”, “bone resorption markers”); the plain word “gas” appears only in the At-A-Glance summary, where item 7.4 mandates plain language, and mirrors the ER Conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present unmodified: lines 446, 491, 539, 644, 672, 819 (headings), 572 and 593 (gates), 676–678 (table headers); tier labels appear in both the Benefits and Risks cards. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 66 named variable spans present, covering page_title, header, at_a_glance, action_1–3, time_1–3, benefits_, stop_items, caution_items, risks_, marker_1–9, monitoring_cadence, and qualitative_item_1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans — website=”evidence_review” (line 423), website=”audit” (426), website=”full_review” (440) — are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped into the QRS is empty; every source section (Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Monitoring) is populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All ten Key Interaction labels reproduce the ER bold labels verbatim including parenthetical drug lists and the Bifidobacterium / Lactobacillus italics; action labels “Standard dose”, “Best time of day”, “Single versus split dosing” match ER 348/358/362. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label deviates from the ER wording; the Time-to-Effect labels are taken from the ER’s own phrases in Practical Considerations (line 405). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur anywhere in the file; the ER’s 🟩/🟥/🟨 tier markers were dropped and tiering is carried by bold labels plus CSS colour. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its minimum consistent with the mandatory-coverage items (9.2, 12.2, 13.2, 14.2, 15.2): gate items reduced to fact-plus-qualifier, tier lines to bare descriptors, and the A4 print rules and small-screen fallbacks in the stylesheet are intact. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: a single comment opening immediately after the doctype on line 1, before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the preceding “QRS — Metadata” caption sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are echoed into any rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: inulin_type_fructans_2026-0825-1843_Opus_ER.md, matching the ER’s own filename frontmatter field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0815-2132, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: inulin_type_fructans_2026-0825-1843_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all eleven keys; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Inulin-Type Fructans for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Inulin-Type Fructans for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/15/2026”, the correct reformatting of qrs_creation_date 2026-0815-2132. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template subline; the ER’s alternate_names list (Inulin, Oligofructose, FOS, …) is correctly absent. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Five clauses map one-to-one onto the four Conclusion paragraphs (ER 477–481), ending on the intake-limiting constraint. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Sentence 1 → ER 477; sentence 2 → ER 477; sentence 3 → ER 479; sentence 4 → ER 479; sentence 5 → ER 481. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; the vocabulary is entirely lay (“plant fibers”, “gut bacteria”, “stool frequency”, “sluggish bowels”, “blood sugar”, “waistline”, “gas”). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size, or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Magnitude is conveyed qualitatively (“modestly”, “favourably but slightly”); no numeric estimates or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from the “Populations who should avoid Inulin-Type Fructans” list at ER 320–326. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-list entries are present, in ER order, with none added or dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 575–588: five <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER trailing clause is stripped: “— absolute contraindication; fructose liberated…”, “— absolute contraindication”, “— defer until remission”, “— avoid pending human data…”, “— avoid unless a supervised reintroduction…”. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(Crohn’s Disease Activity Index above 220, or Mayo score 7 or higher in ulcerative colitis)” and “(Child-Pugh Class B or C, or persistently elevated conjugated bilirubin)” are preserved verbatim, as is “by Rome IV criteria”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking symbols in these parentheticals; thresholds are already written out in words (“above 220”, “7 or higher”, “Class B or C”). |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is not empty — the ER names five avoid populations and all five are carried. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no absence comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items come from the interaction bullets at ER 300–318. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER interaction bullets are present in ER order; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 596–634: ten <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is reduced to the ER’s bold label plus its severity word (“Caution” / “Monitor”); all mechanistic and mitigation sentences are dropped. The only em-dash retained sits inside the ER’s own bold label (“Other fermentable fibers — galactooligosaccharides, resistant starch, partially hydrolysed guar gum”), which items 4.2 and 9.5 require to be kept. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(omeprazole, esomeprazole)”, “(amoxicillin, azithromycin, ciprofloxacin)”, and the prescription / over-the-counter / supplement / other-intervention class markers are all preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheticals contain only class markers and example drug names — no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is not empty — ten interactions are identified and all ten are carried. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no absence comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets come from the ER “Therapeutic Protocol” bullets at lines 348, 358, and 362. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose (“Standard dose”), timing (“Best time of day”), and dose splitting (“Single versus split dosing”) are the three directly executable bullets; the remaining ER bullets are competing approaches, kinetics, or response-modifier discussion. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Protocol section supplies more than three actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans (lines 450–486) carry substantive ER-derived content; none is empty or a placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Bifidobacterial shift, bowel-frequency change, and glycemic improvement are the first three of the four windows the ER lists at line 405; the fourth (body composition) is folded into time_3_sub. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order follows the ER benefit tiering: bifidobacterial expansion and bowel regularity are High-tier benefits, glycemic control is Medium-tier. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER lists four distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Values 1–2 weeks / 2–4 weeks / 6 weeks or more come from ER 405; the subs come from ER 381 (reversal), ER 240 and 405 (gas attenuation), and ER 350 and 405 (10 g dose, body composition window). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet (line 405), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All nine descriptors map to the ER benefit sub-headings at lines 152–216. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 541, 546, 554, 560, each tier populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading with hedging qualifiers removed (“Modest Reduction…” → “reduction in body weight…”; “Small Reductions…” → “reductions in…”); no Magnitude figures, PMIDs, or mechanism text carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four benefit spans; the ER’s “⚠️ Conflicted” markers and Magnitude lines are all dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven descriptors map to the ER risk sub-headings at lines 238–278. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 646, 649, 655, 661, each tier populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; the fermentation, FODMAP, IgE, and rodent-model explanations are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four risk spans; the ER “⚠️ Conflicted” markers and Magnitude lines are dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence come from the ER “Monitoring Protocol & Defining Success” section at lines 433–447. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarker rows are present in ER order — fasting glucose, HbA1c, fasting insulin, triglycerides, LDL-C and ApoB, hs-CRP, red blood cell magnesium, 25-hydroxyvitamin D, Bristol Stool Form Scale type — with targets and “Why” text matching the ER. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 808–813 carry baseline, 12-week, 6–12-month, annual mineral/vitamin D, and 4-week stool-form cadences, all traceable to ER 433–435 and 447. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the “Qualitative markers worth tracking alongside laboratory values” list at ER 449–455. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are present verbatim and in ER order at lines 822–848. |
Issues 15/08/2026 21:42
Pass rate 100.00%. No issues found.
Issues 15/08/2026 21:39
- 2.5 — Imperative protocol cell value: [action_3_value] at line 480 reads “Split above 5 g”, an imperative instruction rather than presented information, breaking parallel with the descriptive cells “5–10 g daily” and “With the largest meal”.
Fixes 15/08/2026 21:39
- 2.5 — Imperative protocol cell value: Changed [action_3_value] from “Split above 5 g” to “Two doses above 5 g”, replacing the imperative instruction with a descriptive noun phrase that matches the ER’s “above 5 g, splitting into two doses”.